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Introduction: The purpose of this study was to assess the value of
tumor response evaluation using combined interpretation of [18F]
fluorodeoxyglucose positron emission tomography (PET) and com-
puted tomography (CT) for the prediction of clinical outcome and
pathologic response in patients with stage III non-small cell lung cancer
who underwent neoadjuvant chemotherapy followed by surgery.
Methods: This study was approved by the Institutional Review
Board with a waiver of informed consent. Forty-four consecutive
patients (M:F  32:12; mean age, 60.7 years) with locally advanced
non-small cell lung cancer received neoadjuvant chemotherapy
followed by curative surgery. Time to recurrence (TTR) was strat-
ified by radiologic, metabolic, and radiologic-metabolic response
using the Kaplan-Meier method. The accuracy of radiologic, meta-
bolic, and radiologic-metabolic response criteria for the prediction
of pathologic response was evaluated.
Results: Radiologic-metabolic responders had a longer TTR than
nonresponders (mean TTR, 58.7 months versus 22.3 months, p 
0.001 with criteria of 30% reduction of size and 50% reduction
of [maximum standardized uptake value] SUVmax and mean TTR,
49.4 months versus 23.5 months, p  0.022 with criteria of 30%
reduction of size and 25% reduction of SUVmax, respectively).
The TTR of radiologic responders (criteria of 30% reduction of
size) and metabolic responders (criteria of 25% reduction of
SUVmax) was not different from the TTR of nonresponders (p 
0.05). The accuracy for the prediction of pathologic response was
70% in radiologic responders, 52 to 75% in metabolic responders,
and 73 to 82% in radiologic-metabolic responders.
Conclusions: Tumor response evaluation using combined interpre-
tation of [18F] fluorodeoxyglucose-PET and CT was more effective
than single interpretation of CT response or PET response alone for
the prediction of tumor recurrence and pathologic response.
Key Words: Non-small cell lung cancer, FDG-PET, Response
Evaluation Criteria in Solid Tumor (RECIST), Response evaluation,
prognosis.
(J Thorac Oncol. 2010;5: 497–503)
Tumor response after chemotherapy reflects the reductionof tumor burden in a patient and can be used as a predictor
of patients’ outcome. Change in size according to RECIST
using a computed tomography (CT) scan is used as a standard
to assess response to therapy, and there have been many
attempts to correlate the change in tumor size on CT with the
pathologic response or survival of patients with non-small
cell lung cancer (NSCLC).1 Recent data have suggested that
tumor response evaluated on [18F] fluorodeoxyglucose
(FDG) positron emission tomography (PET) after chemother-
apy may have a significant correlation with histopathologic
response2–5 or survival6–10 in patients with NSCLC.
Although tumor response on both a CT scan and PET
scan seems to have prognostic significance among patients
with advanced NSCLC, this association has been controver-
sial for patients who have earlier stages of the disease and
undergo neoadjuvant chemotherapy. According to a recent
article by Tanvetyanon et al.,11 among patients with resect-
able NSCLC treated with neoadjuvant chemotherapy, there
was no evidence that tumor response on a PET scan after
chemotherapy was prognostic of survival, although response
on a CT scan was indeed associated with better survival.
However, in contrast, many investigators have suggested the
value of tumor response evaluation using PET scan with one
study reporting that in patients with stage III NSCLC who
underwent neoadjuvant chemotherapy followed by surgery,
the median overall survival was almost four times longer
*Department of Radiology; †Department of Thoracic and Cardiovascular
Surgery, Cancer Research Institute, Xenotransplantation Research Cen-
ter, Clinical Research Center; ‡Department of Pathology; and §Depart-
ment of Nuclear Medicine, Seoul National University Hospital, Seoul,
Republic of Korea.
Disclosure: This study was supported by a grant of the Korea Healthcare
Technology R&D Project, Ministry for Health, Welfare & Family
Affairs, Republic of Korea (Grant No, A090872).
Address for correspondence: Hyun Ju Lee, MD, Department of Radiology,
Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul
110-744, Republic of Korea. E-mail: rosaceci@radiol.snu.ac.kr
Ho Yun Lee, MD, is currently at Department of Radiology and Center for
Imaging Science, Samsung Medical Center, Seoul, Korea.
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0504-0497
Journal of Thoracic Oncology • Volume 5, Number 4, April 2010 497
among patients with no residual glucose metabolism detected
than those with residual glucose hypermetabolism.8 Further-
more, in another study, Vansteenkiste et al.9 showed that a
reduction of greater than 50% of the metabolic activity of the
tumor on PET scan after induction of chemotherapy was asso-
ciated with longer survival in patients with stage III NSCLC.
However, to date, the synergistic value of the combined
evaluation of PET and CT for evaluation of response has not
been evaluated. Therefore, the purpose of this study was to
assess the value of tumor response evaluation using combined
interpretation of FDG-PET and CT for the prediction of
clinical outcome and pathologic response in patients with
stage III NSCLC who underwent neoadjuvant chemotherapy
followed by surgery.
PATIENTS AND METHODS
Patients
Our Institutional Review Board approved this retro-
spective study. Written informed consent was obtained for
the use of CT and PET studies from all patients.
Among 52 consecutive patients with locally advanced
NSCLC who received neoadjuvant chemotherapy between
January 2004 and January 2007 followed by curative surgery,
six patients showing disease progression after neoadjuvant
chemotherapy and two patients lost to follow-up were ex-
cluded. Finally, 44 consecutive patients (M:F  32:12; mean
age, 60.7 years) with locally advanced NSCLC (stages IIIA/
IIIB) who received neoadjuvant chemotherapy followed by
curative surgery were included in this study. All patients
underwent integrated PET/CT and contrast-enhanced chest
and brain CT before (T0) and after neoadjuvant chemother-
apy (T1). Staging procedures included bronchoscopy or me-
diastinoscopy in all patients. Preoperative chemotherapy con-
sisted of two or three cycles with 175 mg/m2 of paclitaxel and
60 mg/m2 of cisplatin.
Imaging and Interpretation
PET and CT scans were first performed less than 2
weeks before neoadjuvant chemotherapy (T0). The second
PET and CT scans were performed 4 weeks after final cycle
of neoadjuvant chemotherapy (T1).
All chest CTs were performed with Sensation-16 (Sie-
mens Medical Systems, Erlangen, Germany), Lightspeed Ul-
tra (GE Medical Systems, Milwaukee, WI), or Mx8000
(Philips Medical Systems, Best, The Netherlands) with 120
kVp, 150 to 200 mAs, pitch of 0.875 to 1.5, collimation of
1 to 2.5 mm, and reconstruction thickness 5 mm. CT
images were acquired after intravenous injection of 100 to
120 ml of Ultravist 370. Two chest radiologists (H.J.L. and
H.Y.L. with 10 and 5 years of experience in thoracic CT
interpretation, respectively) unaware of the clinical and
PET findings and the histologic diagnoses independently
assessed the CT scans.
The longest diameters of all target lesions including
primary tumor and their percentage change after chemother-
apy were measured according to the RECIST.12 Discrepan-
cies in evaluation among the two readers were resolved by
averaging their determined values.
Before intravenous administration of 18F-FDG (5.2
MBq/kg of body weight), patients were instructed to fast for
at least 4 hours to ensure a serum glucose level below 140
mg/dl. Whole body PET images were acquired with the
conventional three-dimensional protocol of 18F-FDG PET
using a Gemini PET/CT camera (Philips Medical Systems,
Cleveland, OH) and a two-slice CT scanner. The resulting
PET and CT images were coregistered on hardware. Low-
dose CT was performed from head to pelvis using a tube
voltage of 120 kV, 50 mA, a tube-rotation time of 0.75
seconds per rotation, a pitch of 1.5, and 6.5 mm reconstruc-
tion thickness, which matched the PET image section thick-
ness. Low-dose CT was acquired for attenuation correction
and anatomic localization without intravenous contrast mate-
rial, with no breath hold. Immediately after CT, emission
PET images were acquired for 2 minutes and 30 seconds per
each bed in three-dimensional acquisition mode. Transaxial
images from 1 hour acquisition of a patient were analyzed for
quantitative analysis. A nuclear medicine physician (K.W.K.
with 10 years of experience in PET/CT interpretation) un-
aware of the clinical and pathologic results evaluated the PET
images. For semiquantitative analysis of FDG uptake, a
region of interest was placed over the most intense area of
FDG accumulation for each patient. FDG uptake within the
region of interest was analyzed by the maximum standardized
uptake value (SUVmax). The maximum SUV was calculated
as decay-corrected activity (kBq) per milliliter of tissue
volume per injected 18F-FDG activity (kBq) per body mass
(g). SUVmax measured in the primary tumor on pre- and
postchemotherapy PET scans were recorded, and the percent
change in the SUVmax was calculated.
Response
Radiologic response was determined using RECIST,
which considers a 30% or greater reduction in the sum of
unidimensional tumor measurements as a response.12 Meta-
bolic response was determined by semiquantitative analysis.
For patients with multiple lesions, the most hypermetabolic
lesion was taken as the index lesion. Metabolic response was
defined as a 25% or greater reduction in the SUVmax as
referred from the EORTC PET response criteria.13 In addi-
tion, an analysis based on a 50% or greater reduction in the
SUVmax was performed.2,8,9 Radiologic-metabolic responses
as a reduction of tumor size of 30% and a reduction of
SUVmax of 25%, 30%, and 50% were analyzed.
Pathologic Response
Pathologic response was used as the reference standard
of therapeutic response. Resected tissues from primary tu-
mors and mediastinal lymph nodes were formalin fixed and
paraffin embedded. An experienced lung pathologist (B.G.J.
with 4 years of experience in lung pathology) retrospectively
interpreted entire tissue sections sliced at 5- to 10-mm inter-
vals and measured the proportion (%) of viable tumor cells in
the primary tumor of the resected surgical specimens. Patho-
logic response was defined as when viable tumor cells con-
stitute less than 10% of the entire pathologic specimen.14 The
presence of residual viable tumor was evaluated in resected
mediastinal lymph nodes.
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Postoperative Follow-Up
After the completion of treatment, patients were fol-
lowed up at 3-month interval with chest CT scans to identify
any disease recurrence for 1 year. When there was no evi-
dence of recurrence during first postoperative year, chest CT
scans were followed at 6-months interval for second postop-
erative year. When there was no evidence of recurrence
during 2 postoperative years, chest CT scans were followed
subsequently at 12-month interval. When there was an evi-
dence of recurrence, additional imaging studies including
whole body FDG-PET, brain MRI, and bone scans were
performed.
Statistical Analysis
Time to recurrence (TTR) was determined using the
Kaplan-Meier method, and TTR curves were stratified by
radiologic, metabolic, radiologic-metabolic, and patho-
logic response criteria. Comparison of the Kaplan-Meier
curves was made by the log-rank test. TTR was measured
from the date of curative resection to the date of detection
of recurrence.
The accuracy of radiologic, metabolic, and radiologic-
metabolic criteria for the prediction of a pathologic response
was evaluated. The percent change (%) in size on CT and
SUVmax of the primary tumor were correlated with the
proportion (%) of viable tumor cells from pathology using
Spearman’s correlation analysis. Cox proportional hazards
regression analysis was used to assess the prognostic value of
response criteria. All analyses were done using SPSS for
Windows, version 12.0 (SPSS, Inc., Chicago, IL).
RESULTS
Patient Demographics
Details of the patient characteristics are summarized in
Table 1. All 44 patients underwent complete surgical resec-
tion and followed by the postoperative follow-up protocol.
The median postoperative follow-up time for all pa-
tients was 24.8 months (range, 3.1–66.2 months). By July
2009, 22 patients (50%) developed recurrent disease after
surgical resection, and the median TTR was 12 months
(range, 4–31 months). Recurrence or metastasis was con-
firmed by specific organ-dedicated or follow-up imaging
studies. The pattern of recurrence was brain metastasis (n 
8), lung metastasis (n  4), recurrence at the resection site
(n  4), metastasis in mediastinal lymph nodes (n  3), bone
metastasis (n  2), and metastasis in extrathoracic lymph
nodes (n  1), respectively.
TTR Based on Tumor Response by CT
Kaplan-Meier survival curves stratified by radiologic,
metabolic, and radiologic-metabolic response criteria are
shown in Figures 1 to 5. The median change in tumor size
was a decrease of 35% (ranging from 3 to 65% decrease)
before and after neoadjuvant chemotherapy. On the basis of
RECIST categories, 23 patients (53%) showed partial re-
sponse and 21 patients (47%) showed stable disease. Com-
paring patients with and without radiologic responses, there
was no significant difference in the TTR between the two
groups (mean TTR, 44.7 months versus 24.5 months and
median TTR, not reached versus 16.8 months, respectively;
p  0.11; Figure 1).
TTR Based on Tumor Response by PET/CT
The median change in the SUVmax before and after
neoadjuvant chemotherapy was a decrease of 45% (ranging
TABLE 1. Patient Characteristics (n  44)
Characteristics Number (%)
Age (y)
Median (range) 61 (40–74)
Sex
Male 32 (73)
Female 12 (27)
Histology
Adenocarcinoma 24 (55)
Squamous cell 17 (39)
Large cell or neuroendocrine 1 (2)
Non-small cell, not specified 2 (4)
Clinical stage
IIIA 36 (82)
IIIB 8 (18)
Procedure
Lobectomy 30 (68)
Bilobectomy 5 (11)
Pneumonectomy 9 (21)
FIGURE 1. Time to recurrence (TTR) based on tumor re-
sponse on computed tomography (CT). Comparing patients
with and without radiologic responses (30% reduction of
tumor size), there was no significant difference in the TTR
between the two groups (mean TTR, 44.7 versus 24.5
months and median TTR, not reached versus 16.8 months,
respectively; p  0.11).
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FIGURE 3. Time to recurrence (TTR) based on tumor re-
sponse by positron emission tomography/computed tomog-
raphy (PET/CT, 50% reduction of SUVmax). Patients with a
metabolic response of 50% reduction of SUVmax had a
longer TTR than patients without response (mean TTR, 51.7
versus 22.7 months and median TTR, not reached versus
18.2 months, respectively; p  0.005). SUVmax, maximum
standardized uptake value.
FIGURE 4. Time to recurrence (TTR) based on radiologic-
metabolic tumor response (30% reduction of tumor size
and 25% reduction of SUVmax). Radiologic-metabolic re-
sponders had a longer TTR than patients with radiologic-
metabolic nonresponse, radiologic response only, and meta-
bolic response only (mean TTR, 49.4 versus 23.5 months
and median TTR not reached versus 16.8 months, respec-
tively; p  0.022). SUVmax, maximum standardized uptake
value.
FIGURE 5. Time to recurrence (TTR) based on radiologic-
metabolic tumor response (30% reduction of tumor size as
well as 50% reduction of SUVmax). Radiologic-metabolic
responders had a longer TTR than patients with radiologic-
metabolic nonresponse, radiologic response only, and meta-
bolic response only (mean TTR, 58.7 months versus 22.3
months and median TTR, not reached versus 16.8 months,
respectively; p  0.001). SUVmax, maximum standardized
uptake value.
FIGURE 2. Time to recurrence (TTR) based on tumor re-
sponse by positron emission tomography/computed tomog-
raphy (PET/CT, 25% reduction of SUVmax). Comparing pa-
tients with and without responses, there was no significant
difference in the TTR between the two groups (mean TTR,
42.1 versus 23.9 months and median TTR, not reached ver-
sus 18.2 months, respectively; p  0.19). SUVmax, maximum
standardized uptake value.
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from 100% decrease to 19% increase). By the response
criteria of 25% reduction of SUVmax, metabolic response
occurred in 31 patients (70%). Comparing patients with and
without responses, there was no significant difference in the
TTR between the two groups (mean TTR, 42.1 months versus
23.9 months and median TTR, not reached versus 18.2
months, respectively; p  0.19; Figure 2).
On the other hand, greater degrees of metabolic re-
sponse seemed to be associated with longer TTR. By the
response criteria of 50% reduction of SUVmax, metabolic
response occurred in 21 patients (48%). Patients with a
metabolic response of 50% reduction of SUVmax had a
longer TTR than patients without response (mean TTR, 51.7
months versus 22.7 months and median TTR, not reached
versus 18.2 months, respectively; p  0.005; Figure 3).
TTR Based on Radiologic-Metabolic Tumor
Response
By the response criteria of 30% reduction of tumor
size and 25% reduction of SUVmax, radiologic-metabolic
response occurred in 20 patients (45%). Radiologic-meta-
bolic nonresponse, radiologic response only, and metabolic
response only were found in 10 (23%), three (7%), and 11
patients (25%), respectively. Radiologic-metabolic respond-
ers had a longer TTR than patients with radiologic-metabolic
nonresponse, radiologic response only, and metabolic re-
sponse only (mean TTR, 49.4 months versus 23.5 months and
median TTR, not reached versus 16.8 months, respectively;
p  0.022; Figure 4).
By the response criteria of 30% reduction of tumor
size and 50% reduction of SUVmax, radiologic-metabolic
response occurred in 16 patients (36%). Radiologic-meta-
bolic nonresponse, radiologic response only, and metabolic
response only were found in 16 (36%), seven (16%), and five
patients (12%), respectively. Radiologic-metabolic respond-
ers had a longer TTR than patients with radiologic-metabolic
nonresponse, radiologic response only, and metabolic re-
sponse only (mean TTR, 58.7 months versus 22.3 months and
median TTR, not reached versus 16.8 months, respectively;
p  0.001; Figure 5).
Correlation between Pathologic, Radiologic,
and Metabolic Response
Supplemental Table 1 (Supplemental Digital Content 1,
http://links.lww.com/JTO/A15) shows the correlation be-
tween pathologic response and tumor response according to
CT and PET. A waterfall plot demonstrating the responses of
all 44 patients is shown in Supplemental Figure 1 (see
Supplemental Digital Content 2, http://links.lww.com/JTO/
A16 for the figure and see Supplemental Digital Content 3,
http://links.lww.com/JTO/A17 for the legend). In the 44 re-
sected tumors, 12 resection specimens (27%) were classified
as pathologic responders (10% of viable tumor cells).
Pathologic response showed a strong and significant correla-
tion with change in size on CT (r  0.63, p  0.0001) and
showed moderate but significant correlation with change in
SUVmax (r  0.48, p  0.001).
The accuracy for the prediction of pathologic response
in radiologic responders (30% reduction of size), metabolic
responders (25% reduction of SUVmax), metabolic respond-
ers (50% reduction of SUVmax), radiologic-metabolic re-
sponders (30% reduction of tumor size as well as 25%
reduction of SUVmax), and radiologic-metabolic responders
(30% reduction of tumor size and 50% reduction of
SUVmax) was 70% (31/44), 52% (23/44), 75% (33/44), 73%
(32/44), and 82% (36/44), respectively.
Kaplan-Meier survival curves stratified by pathologic
response criteria are shown in Figure 6. Patients with a
pathologic response of 10% of viable tumor cells had a
longer TTR than patients without response (mean TTR, 44.2
months versus 31.7 months and median TTR, not reached
versus 23.1 months, respectively; p  0.015). Cox propor-
tional hazards regression analysis showed that pathologic,
radiologic, and metabolic response after neoadjuvant chemo-
therapy provided relevant prognostic information, especially
that the presence of response was inversely related to recur-
rence (Table 2).
Impact of Residual Tumor in Mediastinal
Lymph Nodes
We found a TTR difference between patients who had
no viable tumors and residual viable tumors among medias-
tinal lymph nodes (mean TTR, 48.2 months versus 21.7
months and median TTR, not reached versus 16.8 months,
respectively; p  0.019). Univariate analysis showed that a
residual viable tumor in mediastinal lymph nodes was related
to recurrence (Table 2).
DISCUSSION
In this study, we found that the TTR of radiologic-
metabolic responders was significantly longer than the TTR
of radiologic responders only and metabolic responders only.
Therefore, combined evaluation of CT response and PET
response may be more effective than single interpretation
FIGURE 6. Time to recurrence (TTR) based on pathologic
response. Patients with a pathologic response of 10% of
viable tumor cells had a longer TTR than patients without
response (mean TTR, 44.2 months versus 31.7 months and
median TTR, not reached versus 23.1 months, respectively;
p  0.015).
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using CT response or PET response alone for the prediction
of tumor recurrence in patients with stage III NSCLC who
underwent neoadjuvant chemotherapy followed by surgery.
Moreover, the accuracy for the prediction of pathologic
response was higher when combined evaluation of CT re-
sponse, and PET response was performed compared with
single interpretation of CT response or PET response.
Unfortunately, the value of CT or PET alone as a
predictor of patients’ outcome remains unclear and contro-
versial. The reason for the controversial results regarding
RECIST is that there have been no clear data to support that
a change in tumor size on radiologic studies accurately
reflects survival. In fact, lung tumors are heterogeneous, and
therefore, the host response against therapy is inevitably
variable. For instance, chemotherapy, in some instances, may
destroy only the susceptible tumor cells, and more virulent
resistant tumor cells may continue to proliferate,15 but in
other instances, a robust host inflammatory response to the
tumor itself may produce the majority of the radiologic
abnormalities.16–18 Therefore, the concept that tumor cell
response equals tumor size response needs to be reconsid-
ered. The controversial results of FDG-PET may be related to
the fact that the exact mechanism of FDG uptake and distri-
bution within the various cells in a tumor remains unclear.
However, despite of these limitations of RECIST on
CT or PET scan, there is currently no alternative approach to
response evaluation, and patients should still be observed
with CT or PET scan. From this study, we propose that a
combined interpretation of FDG-PET and RECIST provides
more reliable information of morphologic and functional
changes and would be helpful for stratifying patients with
locally advanced NSCLC for therapy and predicting patient
outcomes. The value of combining CT response to FDG-PET
response was especially more obvious in patients with lower
degrees of metabolic response than in patients with higher
degrees of metabolic response.
We applied two cutoff values as the standard for
metabolic response in our study. According to our study
results, metabolic responders of 50% reduction of SU-
Vmax had a longer TTR than patients of 25% reduction of
SUVmax (mean TTR, 51.7 versus 42.1 months, respec-
tively). Moreover, a significant difference in TTR between
metabolic responders and nonresponders was only found
by the response criteria of 50% reduction of SUVmax.
These differences were consistently shown in the evalua-
tion of radiologic-metabolic response. In terms of the
accuracy for the prediction of pathologic response, greater
degrees of metabolic response also seemed to be associ-
ated with higher accuracy.
We performed analysis incorporating the status of a
residual viable tumor in mediastinal lymph nodes after neo-
adjuvant chemotherapy, because the nodal down staging of
initial N2 or N3 involvement to N0 status in the mediastinum
have been shown to be strong predictors of better clinical
outcome after neoadjuvant chemotherapy or chemoradiother-
apy.19–26 Our findings are consistent with those reports. TTR
was significantly different between patients who had no
viable tumors and those with a residual viable tumor in
mediastinal lymph nodes, and the presence of a residual
viable tumor in mediastinal lymph nodes was a significant
prognostic indicator of shorter TTR.
Our study was limited inherently by its retrospective
design; however, we dealt with a consecutive data in patients
with a homogenous stage III NSCLC in a single tertiary
hospital thereby possibly minimizing selection bias. Another
limitation is the small number of subjects included in our
study. Therefore, the clinical assessment of combined criteria
using RECIST and PET for prediction of response to chemo-
therapy requires further investigation with a prospective de-
sign and a larger population.
The proportion of viable tumors in the primary tumor of
the surgical resected specimen may not exactly reflect a
pathologic response. The predominant cause for the discor-
dance between the response to neoadjuvant therapy and the
extent of histomorphologically determined tumor regression is
the fact that vital tumor cannot be differentiated from already
necrotic tumor tissue or scar formations even in any evaluation
method. However, Junker’s score that we adopted14 has been
frequently used for the definition of pathologic responder and
nonresponder after the neoadjuvant therapy because there has
not been better standard reference.
In conclusion, tumor response evaluation using com-
bined interpretation of FDG-PET and CT was more effective
than the single interpretation of CT response or PET response
alone for the prediction of tumor recurrence and pathologic
response in patients with stage III NSCLC who underwent
neoadjuvant chemotherapy followed by surgery.
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